LCM
UTHR icon

Laurion Capital Management’s United Therapeutics UTHR Stock Holding History

Laurion Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-250,000
Closed -$32.4M – 1914
2017
Q2 		$32.4M Hold
250,000
– – 0.18% 113
2017
Q1 		$33.8M Buy
+250,000
New +$37.9M 0.25% 94

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Laurion Capital Management's UTHR Position: Q1 2026 in Review

Laurion Capital Management sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 670 shares — an estimated $326K sold.

Laurion Capital Management first reported a position in UTHR in Q3 2016 and held it in 11 quarters. The position peaked at $20.3M in Q2 2017. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Laurion Capital Management reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Laurion Capital Management sold 670 United Therapeutics shares in Q1 2026, an estimated $326K.
  • Laurion Capital Management first reported a position in United Therapeutics in Q3 2016 and held it in 11 quarters.
  • Laurion Capital Management's United Therapeutics position peaked at $20.3M in Q2 2017.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.